Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M. Younossi, Victor Ankoma‐Sey, James F. Trotter et al.|The Lancet|2019Cited by 1.2k
Impact of Hepatopulmonary Syndrome on Quality of Life and Survival in Liver Transplant CandidatesMichael B. Fallon, Steven M. Kawut, Michael J. Krowka et al.|Gastroenterology|2008Cited by 306
Clinical risk factors for portopulmonary hypertension†Steven M. Kawut, Michael B. Fallon, Michael J. Krowka et al.|Hepatology|2008Cited by 286
Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver DiseaseKari E. Roberts, Steven M. Kawut, Michael B. Fallon et al.|American Journal of Respiratory and Critical Care Medicine|2009Cited by 232
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a TrialRohit Loomba, George Kemble, Rizwana Mohseni et al.|Gastroenterology|2021Cited by 216